UCB seeks approval for new Crohn’s disease treatment
If approved, Cimzia (certolizumab pegol, CDP870) would be the first-ever biologic utilizing subcutaneous injection for the treatment of Crohn’s disease. It is the first and only PEGylated Fab’
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.